Dr. George Church is a Professor of Genetics at Harvard Medical School and a co-founder of multiple biotech companies. In this wide-ranging interview, he speaks about his work on de-extinction, his vision of a future without age-related illness, and his AI-powered startups.

Karandeep Singh, MD, MMSc, is an Assistant Professor of Learning Health Sciences, Internal Medicine, Urology, and Information at the University of Michigan. He speaks with us about bridging the gap between academia and practice and discusses how the University of Michigan deploys and rigorously evaluates machine learning models in real clinical practice.

Luis Voloch is Co-Founder and Chief Technology Officer at Immunai, which is applying AI to immunology, genomics and drug discovery. He speaks with us about how Immunai is using AI to build a comprehensive, top-of-the-tree view of the immune system.

Dr. Suchi Saria is the Founder and CEO of Bayesian Health, the John C. Malone Associate Professor of computer science, statistics, and health policy, and the Director of the Machine Learning and Healthcare Lab at Johns Hopkins University. She speaks with us on how Bayesian Health uses insights from electronic health records to detect diseases and improve patient outcomes.

Dr. Panch is a primary care physician, the Co-Founder of Wellframe, and an instructor at the Harvard T.H. Chan School of Public Health. He speaks with us about Wellframe's work on demystifying complex care regimens, providing personalized support to patients, and understanding social issues affecting healthcare. He also discusses entrepreneurship strategies, the role of academic research, and the future of medical AI regulation.

Dr. Krishna Yeshwant is Managing Partner of GV. In addition to working with GV since its inception, he has earned degrees in computer science, medicine and business, and he practiced at Brigham and Women’s Hospital in Boston, Massachusetts for several years. He speaks with us about different segments of the healthcare market and the role of investors in improving medicine.

Julie Yoo is a General Partner at Andreessen Horowitz where she leads investments in healthcare technology. Prior to joining a16z, Julie was the co-founder, Chief Product Officer, and Board Director at Kyruus, a venture-backed health tech company recognized as a market leader in patient access. She speaks with us about opportunities in digital healthcare, Andreessen Horowitz’s approach to healthcare investing, and her journey from operator to investor.

Nan Li is Managing Director of Obvious Ventures, leading investments in computational biology visionaries, AI-driven platforms and intelligent robotics companies. He speaks with us on how AI and advances in physical tools are industrializing drug discovery, allowing new medicines to be found at a previously unprecedented pace.

Joshua A. Gordon, M.D., Ph.D. is the Director of the National Institute of Mental Health (NIMH), the lead federal agency for research on mental disorders. He speaks with us about how AI can be used to provide more accurate psychiatric diagnoses and better target treatments for mental illnesses.

Dr. Susan Athey is the Economics of Technology Professor at Stanford Graduate School of Business and the Associate Director of the Stanford Institute for Human-Centered Artificial Intelligence. She speaks with us about how AI is reshaping medicine and the economy as a whole, and she discusses the role of businesses, legislators and universities in ensuring that AI is used ethically.